IS1935B - Fósínópríl lyfjasamsetning - Google Patents
Fósínópríl lyfjasamsetningInfo
- Publication number
- IS1935B IS1935B IS6315A IS6315A IS1935B IS 1935 B IS1935 B IS 1935B IS 6315 A IS6315 A IS 6315A IS 6315 A IS6315 A IS 6315A IS 1935 B IS1935 B IS 1935B
- Authority
- IS
- Iceland
- Prior art keywords
- fosinopril
- pharmaceutical composition
- formulation
- fosinoprilat
- ace
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS6315A IS1935B (is) | 2002-03-19 | 2002-03-19 | Fósínópríl lyfjasamsetning |
US10/507,918 US7045511B2 (en) | 2002-03-19 | 2003-03-19 | Fosinopril formulation |
PCT/IS2003/000013 WO2003077929A1 (en) | 2002-03-19 | 2003-03-19 | Fosinopril formulation |
PT03706893T PT1531831E (pt) | 2002-03-19 | 2003-03-19 | Formulacao de fosinopril |
UA20041008392A UA78988C2 (en) | 2002-03-19 | 2003-03-19 | Pharmaceutical formulation comprising fosinopril |
EA200401218A EA008171B1 (ru) | 2002-03-19 | 2003-03-19 | Фармацевтическая композиция, содержащая фозиноприл |
AT03706893T ATE314076T1 (de) | 2002-03-19 | 2003-03-19 | Fosinopril-formulierung |
EP03706893A EP1531831B1 (en) | 2002-03-19 | 2003-03-19 | Fosinopril formulation |
AU2003208599A AU2003208599A1 (en) | 2002-03-19 | 2003-03-19 | Fosinopril formulation |
DE60303041T DE60303041T2 (de) | 2002-03-19 | 2003-03-19 | Fosinopril-formulierung |
DK03706893T DK1531831T3 (da) | 2002-03-19 | 2003-03-19 | Fosinoprilformulering |
ES03706893T ES2256721T3 (es) | 2002-03-19 | 2003-03-19 | Formulacion de fosinopril. |
NO20044390A NO20044390L (no) | 2002-03-19 | 2004-10-18 | Fosinoprilformulering |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS6315A IS1935B (is) | 2002-03-19 | 2002-03-19 | Fósínópríl lyfjasamsetning |
Publications (2)
Publication Number | Publication Date |
---|---|
IS6315A IS6315A (is) | 2003-09-20 |
IS1935B true IS1935B (is) | 2004-06-16 |
Family
ID=36715398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6315A IS1935B (is) | 2002-03-19 | 2002-03-19 | Fósínópríl lyfjasamsetning |
Country Status (13)
Country | Link |
---|---|
US (1) | US7045511B2 (is) |
EP (1) | EP1531831B1 (is) |
AT (1) | ATE314076T1 (is) |
AU (1) | AU2003208599A1 (is) |
DE (1) | DE60303041T2 (is) |
DK (1) | DK1531831T3 (is) |
EA (1) | EA008171B1 (is) |
ES (1) | ES2256721T3 (is) |
IS (1) | IS1935B (is) |
NO (1) | NO20044390L (is) |
PT (1) | PT1531831E (is) |
UA (1) | UA78988C2 (is) |
WO (1) | WO2003077929A1 (is) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050069586A1 (en) * | 2003-06-26 | 2005-03-31 | Julia Hrakovsky | Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives |
US20050095287A1 (en) * | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
GB2411355B (en) * | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
ES2318731T3 (es) * | 2005-02-11 | 2009-05-01 | Aventis Pharmaceuticals Inc. | Esteres de acido propano-fosfinico sustituido. |
WO2006100602A2 (en) * | 2005-03-22 | 2006-09-28 | Aurobindo Pharma Ltd | Immediate release stable solid oral dosage forms op fosinopril |
WO2007120930A2 (en) * | 2006-04-19 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
PT1889629E (pt) * | 2006-07-10 | 2008-10-20 | Teva Pharma | Formulação estável compreendendo uma associação de um fármaco sensível à humidade e de um segundo fármaco e processo para o seu fabrico |
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4337201A (en) * | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US5006344A (en) * | 1989-07-10 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Fosinopril tablet formulations |
US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
CA2330904C (en) * | 2001-01-11 | 2006-10-24 | Bernard Charles Sherman | Fosinopril sodium tablet formulation |
HUP0401998A2 (hu) * | 2001-11-02 | 2005-01-28 | Pfizer Products Inc., | PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető |
ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
-
2002
- 2002-03-19 IS IS6315A patent/IS1935B/is unknown
-
2003
- 2003-03-19 UA UA20041008392A patent/UA78988C2/uk unknown
- 2003-03-19 US US10/507,918 patent/US7045511B2/en not_active Expired - Fee Related
- 2003-03-19 AU AU2003208599A patent/AU2003208599A1/en not_active Abandoned
- 2003-03-19 DE DE60303041T patent/DE60303041T2/de not_active Expired - Lifetime
- 2003-03-19 EA EA200401218A patent/EA008171B1/ru not_active IP Right Cessation
- 2003-03-19 EP EP03706893A patent/EP1531831B1/en not_active Expired - Lifetime
- 2003-03-19 DK DK03706893T patent/DK1531831T3/da active
- 2003-03-19 WO PCT/IS2003/000013 patent/WO2003077929A1/en not_active Application Discontinuation
- 2003-03-19 PT PT03706893T patent/PT1531831E/pt unknown
- 2003-03-19 AT AT03706893T patent/ATE314076T1/de active
- 2003-03-19 ES ES03706893T patent/ES2256721T3/es not_active Expired - Lifetime
-
2004
- 2004-10-18 NO NO20044390A patent/NO20044390L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA008171B1 (ru) | 2007-04-27 |
US7045511B2 (en) | 2006-05-16 |
DK1531831T3 (da) | 2006-05-15 |
IS6315A (is) | 2003-09-20 |
DE60303041T2 (de) | 2006-08-24 |
AU2003208599A1 (en) | 2003-09-29 |
NO20044390L (no) | 2004-12-15 |
ATE314076T1 (de) | 2006-01-15 |
EP1531831B1 (en) | 2005-12-28 |
US20050256086A1 (en) | 2005-11-17 |
PT1531831E (pt) | 2006-05-31 |
EP1531831A1 (en) | 2005-05-25 |
DE60303041D1 (de) | 2006-02-02 |
ES2256721T3 (es) | 2006-07-16 |
UA78988C2 (en) | 2007-05-10 |
EA200401218A1 (ru) | 2005-12-29 |
WO2003077929A1 (en) | 2003-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1076605A1 (en) | Formulations | |
CY1109457T1 (el) | Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει | |
TW200621313A (en) | Pharmaceutical compositions | |
MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
BR0209431A (pt) | Novos compostos de 4-anilinoquinolino-3-carboxamidas | |
MY140841A (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
SG10201809390QA (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
MA29857B1 (fr) | Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases | |
MX2009003926A (es) | Composiciones de fenilalquilamino-carbamato. | |
ATE529430T1 (de) | Caspase-hemmer-propharmaka | |
EA200601608A1 (ru) | Способ производства твёрдой фармацевтической композиции | |
MA29858B1 (fr) | Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases | |
ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
MX2009003929A (es) | Composiciones de fenilalquil carbamato. | |
IS6315A (is) | Fósínópríl lyfjasamsetning | |
MXPA04006266A (es) | Pirimidotriazinas como inhibidores de fosfatasa. | |
BR0311327A (pt) | Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo | |
NO20083183L (no) | Fast farmasoytisk sammensetning inneholdende irbesartan | |
WO2008036316A3 (en) | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
BRPI0411218A (pt) | formulações alvejantes fluorescentes estáveis em estocagem | |
TW200640860A (en) | Lercanidipine free base | |
MXPA06000636A (es) | Formulaciones semi-solidas para la administracion oral de taxoides. | |
WO2005072736A3 (en) | Stable gabapentin compositions | |
SI1546083T1 (sl) | Nove substituirane arilheksadienojske kisline in njihovi estri ki se lahko uporabljajo za zdravljenje in preprečevanje diabetesa dislipidemije in ateroskleroze farmacevtski sestavki ki jih vsebujejo in postopek njihove priprave |